BioCentury

7:00 AM GMT, Jun 10, 2013
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulatory

Xtandi enzalutamide regulatory update

Astellas and Medivation said Health Canada approved Xtandi enzalutamide to treat metastatic

Read the full 123 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.